| NICE Diagnostics Guidance |
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules DG46 |
| NICE Diagnostics Guidance |
EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer DG9 |
| NICE Guideline |
Lung cancer: diagnosis and management NG122 |
| NICE Interventional Procedures Guidance |
Irreversible electroporation for treating primary lung cancer and metastases in the lung IPG441 |
| NICE Interventional Procedures Guidance |
Microwave ablation for primary or metastatic cancer in the lung IPG716 |
NICE Interventional Procedures Guidance |
Percutaneous radiofrequency ablation for primary or secondary lung cancers IPG372 |
| NICE Interventional Procedures Guidance |
Photodynamic therapy for localised inoperable endobronchial cancer IPG137 |
| NICE Technology Appraisal |
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) TA444 |
| NICE Technology Appraisal |
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) TA438 |
| NICE Technology Appraisal |
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) TA618 |
| NICE Technology Appraisal |
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) TA148 |
| NICE Technology Appraisal |
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) TA436 |
| NICE Technology Appraisal |
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) TA848 |
| NICE Technology Appraisal |
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) TA564 |
| NICE Technology Appraisal |
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) TA662 |
| NICE Technology Appraisal |
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) TA362 |
| NICE Technology Appraisal |
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) TA635 |
| NICE Technology Appraisal Guidance |
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer TA536 |
| NICE Technology Appraisal Guidance |
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy TA850 |
| NICE Technology Appraisal Guidance |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer TA823 |
| NICE Technology Appraisal Guidance |
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA520 |
| NICE Technology Appraisal Guidance |
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA584 |
| NICE Technology Appraisal Guidance |
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer TA705 |
| NICE Technology Appraisal Guidance |
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA638 |
| NICE Technology Appraisal Guidance |
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor TA670 |
| NICE Technology Appraisal Guidance |
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib TA571 |
| NICE Technology Appraisal Guidance |
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) TA884 |
| NICE Technology Appraisal Guidance |
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer TA395 |
| NICE Technology Appraisal Guidance |
Certinib for untreated ALK-positive non-small-cell lung cancer TA500 |
| NICE Technology Appraisal Guidance |
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer TA422 |
| NICE Technology Appraisal Guidance |
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer TA529 |
| NICE Technology Appraisal Guidance |
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer TA406 |
| NICE Technology Appraisal Guidance |
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer TA595 |
| NICE Technology Appraisal Guidance |
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer TA898 |
| NICE Technology Appraisal Guidance |
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation TA798 |
| NICE Technology Appraisal Guidance |
Elotinib monotherapy for maintenance treatment of non-small-cell lung cancer TA227 |
| NICE Technology Appraisal Guidance |
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA643 |
| NICE Technology Appraisal Guidance |
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy TA374 |
| NICE Technology Appraisal Guidance |
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer TA258 |
| NICE Technology Appraisal Guidance |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer TA192 |
| NICE Technology Appraisal Guidance |
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer TA628 |
| NICE Technology Appraisal Guidance |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer TA909 |
| NICE Technology Appraisal Guidance |
Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy TA855 |
| NICE Technology Appraisal Guidance |
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer TA411 |
| NICE Technology Appraisal Guidance |
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer TA347 |
| NICE Technology Appraisal Guidance |
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy TA655 |
| NICE Technology Appraisal Guidance |
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy TA713 |
| NICE Technology Appraisal Guidance |
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer TA724 |
| NICE Technology Appraisal Guidance |
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection TA761 |
| NICE Technology Appraisal Guidance |
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer TA653 |
| NICE Technology Appraisal Guidance |
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer TA654 |
| NICE Technology Appraisal Guidance |
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy TA428 |
| NICE Technology Appraisal Guidance |
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA531 |
| NICE Technology Appraisal Guidance |
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer TA770 |
| NICE Technology Appraisal Guidance |
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA683 |
| NICE Technology Appraisal Guidance |
Pemetrexed for the first-line treatment of non-small-cell lung cancer TA181 |
| NICE Technology Appraisal Guidance |
Pemetrexed for the maintenance treatment of non-small-cell lung cancer TA190 |
| NICE Technology Appraisal Guidance |
Pemetrexed for the treatment of non-small-cell lung cancer TA124 |
| NICE Technology Appraisal Guidance |
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin TA402 |
| NICE Technology Appraisal Guidance |
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer TA812 |
| NICE Technology Appraisal Guidance |
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer TA403 |
| NICE Technology Appraisal Guidance |
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer TA760 |
| NICE Technology Appraisal Guidance |
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer TA781 |
| NICE Technology Appraisal Guidance |
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations TA789 |
| NICE Technology Appraisal Guidance |
Topotecan for the treatment of relapsed small-cell lung cancer TA184 |
